Results 61 to 70 of about 1,446 (206)

The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease.

PLoS ONE, 2015
The progressive degeneration of the dopamine neurons of the pars compacta of substantia nigra and the consequent loss of the dopamine innervation of the striatum leads to the impairment of motor behavior in Parkinson's disease.
Luis F Razgado-Hernandez, Armando J Espadas-Alvarez, Patricia Reyna-Velazquez, Arturo Sierra-Sanchez, Veronica Anaya-Martinez, Ismael Jimenez-Estrada, Michael J Bannon, Daniel Martinez-Fong, Jorge Aceves-Ruiz   +8 more
doaj   +1 more source

Circadian‐timed dopamine agonist treatment reverses high‐fat diet‐induced diabetogenic shift in ventromedial hypothalamic glucose sensing

Endocrinology, Diabetes & Metabolism, 2020
Introduction Within the ventromedial hypothalamus (VMH), glucose inhibitory (GI) neurons sense hypoglycaemia while glucose excitatory (GE) neurons sense hyperglycaemia to initiate counter control mechanisms under normal conditions.
Carl R. Stoelzel, Yahong Zhang, Anthony H. Cincotta   +2 more
doaj   +1 more source

Clinical Algorithm‐Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Axial postural abnormalities (APAs) are common, disabling complications of Parkinson's disease (PD) with unclear pathophysiology. The presence of hyperactivity in multiple trunk muscles supports the use of botulinum toxin (BTA). However, its application is complex, due to the lack of standardized clinical and electrophysiological ...
Giacomo Argenziano, Giovanna Squintani, Serena Camozzi, Ilaria Di Vico, Marialuisa Gandolfi, Carlo Alberto Artusi, Michele Tinazzi, Christian Geroin   +7 more
wiley   +1 more source

Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome

Scientific Reports
Mitochondrial diseases are mainly caused by dysfunction of mitochondrial respiratory chain complexes and have a variety of genetic variants or phenotypes. There are only a few approved treatments, and fundamental therapies are yet to be developed.
Mizuki Kobayashi, Akihiko Miyauchi, Eriko F. Jimbo, Natsumi Oishi, Shiho Aoki, Miyuki Watanabe, Yasushi Yoshikawa, Yutaka Akiyama, Takanori Yamagata, Hitoshi Osaka   +9 more
doaj   +1 more source

Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visual hallucinations (VH) and mild cognitive impairment (MCI) often co‐occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co‐occurrence, and whether this relationship ...
Sabrina M. Adamo, Vaishali Mutreja, Marta Statucka, Batu Kaya, Taylor W. Schmitz, Anthony C. Ruocco, Melanie Cohn   +6 more
wiley   +1 more source

Untreated Giant Macroprolactinoma with Chronic Cerebrospinal Fluid Leakage: An Unusual Complication

Case Reports in Endocrinology, 2019
Macroprolactinoma has the potential to cause base of skull erosion and often extends into the sphenoid sinus. Rapid shrinkage of this invasive tumor following dopamine agonist therapy has been postulated to cause unplugging of the eroded area, leading to
Mohamad Nazrulhisham Mad Naser, Nor Azizah Aziz, Noor Khairiah A. Karim   +2 more
doaj   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model

Neurobiology of Disease, 2004
Brain cannabinoid CB1 receptors are expressed in neural areas that contribute to movement such as basal ganglia, where they co-localize with dopamine D1 and D2 receptors.
Fadwa El Banoua, Isabel Caraballo, Juan A Flores, Beatriz Galan-Rodriguez, Emilio Fernandez-Espejo   +4 more
doaj   +1 more source

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Effective drug treatment of motor and non‐motor symptoms in Parkinson's disease (PD) often requires the administration of several anti‐Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge ...
Stephan Greten, Sarana Ulaganathan, Johannes Heck, Lan Ye, Matthias Höllerhage, Christoph Schrader, Corinna Ziemann, Olaf Krause, Florian Wegner, Martin Klietz   +9 more
wiley   +1 more source

Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human α-synuclein in mice

Neurobiology of Disease, 2006
Genetic and biochemical abnormalities associated with α-synuclein are implicated in the etiology of Parkinson's disease (PD). In this study, altered locomotor behavior linked to the expression of mutant or wildtype human α-synuclein was investigated ...
Erica L. Unger, David J. Eve, Xiomara A. Perez, Dawn K. Reichenbach, Yanqun Xu, Michael K. Lee, Anne M. Andrews   +6 more
doaj   +1 more source